GLP1R and type 2 diabetes mellitus: Chaudhuri et al. demonstrated that in 24 obese persons with T2D, 12 weeks of treatment with the GLP-1 RA exenatide reduced PBMC mRNA expression of TNFA and IL1B compared to placebo18.